### Accepted Manuscript


Impact of treatment modality on quality of life of head and neck cancer patients: Findings from an academic medical institution

Kara Christopher

 PII:
 S0196-0709(16)30281-2

 DOI:
 doi:10.1016/j.amjoto.2016.12.003

 Reference:
 YAJOT 1780



To appear in: American Journal of Otolaryngology–Head and Neck Medicine and Surgery

Received date: 30 August 2016

Please cite this article as: Christopher Kara, Impact of treatment modality on quality of life of head and neck cancer patients: Findings from an academic medical institution, *American Journal of Otolaryngology–Head and Neck Medicine and Surgery* (2016), doi:10.1016/j.amjoto.2016.12.003

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## ACCEPTED MANUSCRIPT

#### Impact of treatment modality on quality of life of head and neck cancer patients: Findings from an academic medical institution

#### Introduction

Kara Christopher nosazuwa@slu.edu

Dr Nosayaba Osazuwa-Peters Saint Louis University 6th Floor Desloge Building 3635 Vista Avenue Saint Louis, Missouri 63110-2539 United States

There are approximately 436,000 head and neck cancer survivors in the United States currently [1], with 5-year survival rates reported at 63.2% for oral cavity and pharynx and 60.6% for larynx [2]. Virtually all head and neck cancer (HNC) patients present with one or more oral or dental complications [3], which can be mild and include discomfort and pain, or more serious, with morbidities such as dysphagia, mucositis, xerostomia or osteoradionecrosis [4-6]. Further, these complications impact quality of life (QOL) long after treatment [5]. Increasing survival rates among HNC patients emphasize the importance of long-term management of these issues in order to optimize health and well-being [5].

Selection of treatment modality and survival among those with HNC are both related to clinical stage at presentation [7]. When patients present with localized tumors (stage I or II), surgery or radiation therapy is usually the treatment of choice, and such single modality treatment usually has a better prognosis and lesser functional and QOL impact [7]. Unfortunately, a majority of patients tend to present with later stages (III and IV) [7, 8], often requiring a combination of surgery, radiation therapy, and/or chemotherapy [7]. These treatment modalities have a profound effect on QOL; surgical and non-surgical modalities (radiation therapy and chemotherapy) have shown similar survival benefits,

1

Download English Version:

# https://daneshyari.com/en/article/5713666

Download Persian Version:

https://daneshyari.com/article/5713666

Daneshyari.com